Companion Diagnostics: Technologies and Markets
Report Highlights
The global market for companion diagnostics reached nearly $3.2 billion in 2015. This market is expected to increase from $4.3 billion in 2016 to nearly $17.6 billion in 2021 at a compound annual growth rate (CAGR) of 32.3% for 2016-2021.
Report Includes
- An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments.
- Analyses of market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry.
- Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments.
- Profiles of major players as well as a list of current companies that have new companion diagnostics products in development.
Report Scope
The scope of the report encompasses the major types of diagnostics technologies that have been used, the various industry structures such as the lab developed tests (LDTs) sector, and the major applications being commercialized and developed by a wide range of company types. It analyzes current market status, examines future market drivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed.
Analyst Credentials
Robert Hunter is a senior management consultant, commercialization consultant and technology and market analyst with over 20 years of experience in life sciences and healthcare. Recent consulting includes market/technology analysis and forecasting of customer adoption and revenue for a high content screening (HCS) technology leader. He is an early investor in a company using stem cells for predictive drug safety testing in vitro. He has a B.S. in Mechanical Engineering from Clemson University and Master of Business Administration from The Tuck School of Business at Dartmouth.
Report Highlights
The global companion diagnostics market reached $1.1 billion in 2012. The market is expected to grow to $1.2 billion in 2013 and $3.5 billion in 2018 with a compound annual growth rate (CAGR) of 23.9%.
Report Includes
- An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments.
- Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry.
- Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments.
- Comprehensive company profiles of major players, as well as a list of current companies that have new companion diagnostics products in development.
Report Highlights
-
Oncotype Dx, although not FDA-approved, is still a lead product in the breast cancer diagnosis sector. Oncotype Dx is reimbursed by most insurance companies and therefore enjoys an increase in its sales number every year. Valued at $170 million in 2010, analysts believe that by 2015, Oncotype Dx for breast cancer risk recurrence and drug regimen may reach $300 million, a compound annual growth rate (CAGR) of 12%.
-
The approval of Selzentry for first time HIV patients is creating new opportunity for the assay Trofile, a companion diagnostic to Selzentry (Celsentri outside U.S.). As a result, Trofile is expected to reach an estimated $34 million by 2015, from $24 million in 2010, a compound annual growth rate (CAGR) of 7.2%.